Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SKB264 |
Synonyms | |
Therapy Description |
SKB264 is an antibody-drug conjugate consisting of a monoclonal antibody that targets trophoblast cell surface protein 2 (TROP2) linked to an undisclosed cytotoxic agent, which delivers the drug to TROP2-expressing tumor cells, potentially inhibiting tumor cell proliferation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SKB264 | SKB 264|SKB-264|ADC SKB264|MK-2870|MK 2870|MK2870 | TROP2 Antibody 7 | SKB264 is an antibody-drug conjugate consisting of a monoclonal antibody that targets trophoblast cell surface protein 2 (TROP2) linked to an undisclosed cytotoxic agent, which delivers the drug to TROP2-expressing tumor cells, potentially inhibiting tumor cell proliferation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06132958 | Phase III | Paclitaxel Doxorubicin SKB264 | MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) | Recruiting | USA | NLD | FRA | ESP | CAN | AUS | 9 |
NCT06074588 | Phase III | Docetaxel SKB264 Pemetrexed Disodium | MK-2870 Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Recruiting | USA | CAN | AUS | 6 |
NCT04152499 | Phase Ib/II | SKB264 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Recruiting | USA | 1 |